A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

To evaluate the safety and tolerability of MEDI0562 in adult subjects with selected advanced solid tumors

Key facts

Study ID

NCT02318394

Run by

MedImmune LLC

People needed

56

Starts

2015-03-02

Expected to finish

2018-01-09

Last updated by the study team

2018-01-29

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have confirmed advanced solid tumor and have progressed, are refractory, or are intolerant to standard therapy appropriate for tumor type. Subjects should not have received more than 3 prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies.
• Subjects must have at least 1 measurable lesion.
• Consent to provide archived tumor specimens
• Willingness to undergo pre-treatment and on-treatment biopsy.
• Adequate organ function.
• Use of highly effective contraception (females) or male condom plus spermicide (males).

You may not qualify if…

• Prior treatment with TNFRSF agonists.
• Subjects who have received certain prior immunotherapy or had toxicities relating to prior immunotherapy may not be permitted to enroll.
• o Must not have required the use of additional immunosuppression other than corticosteroids for the management of an adverse event.
• History of severe allergic reactions to any unknown allergens or any components of the study drug formulations.
• Receipt of any conventional or investigational anticancer therapy within 28 days prior to the first dose of MEDI0562.
• Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.
• Unresolved toxicities from prior anticancer therapy.
• Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.

Where it is running

• Research Site — La Jolla, California, United States
• Research Site — Ann Arbor, Michigan, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Minneapolis, Minnesota, United States
• Research Site — New York, New York, United States
• Research Site — The Bronx, New York, United States
• Research Site — Huntersville, North Carolina, United States
• Research Site — Portland, Oregon, United States
• Research Site — Pittsburgh, Pennsylvania, United States
• Research Site — Dallas, Texas, United States
• Research Site — Houston, Texas, United States
• Research Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.